Drug Type Bispecific antibody |
Synonyms- |
Target |
Mechanism IL-27 inhibitors(Interleukin-27 subunit alpha inhibitors), IL6RB antagonists(Interleukin-6 receptor subunit beta antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammatory Bowel Diseases | Preclinical | US | 15 Feb 2024 |